A carregar cotações...
Previsão
O preço-alvo médio dos analistas é € 92,83 (-10,00%). A mediana é € 93,79 (-9,07%).
| Comprar |
15 |
| Manter |
1 |
| Vender |
0 |
Notícias Ir para o feed de notícias
Hinge Health expects significant earnings jump in quarter ended 30 September 2026
Hinge Health will release results for the quarter ended 30 September 2026 on 2 November 2026. On average, 13 analysts expect earnings of $0.576 per share versus −$0.020 in the year‑ago quarter; average revenue expectations (14 analysts) are $224.8 million (up 45.8% year‑over‑year). For the current fiscal year, 12 analysts on average forecast earnings per share of $2.32 and 16 analysts forecast revenue of $860.6 million. » Mais em finanzen.net
Hinge Health expands digital pain therapy for employers and insurers
Hinge Health generates recurring revenue by having large employers and insurers pay for digital pain therapies to avoid costly surgeries. The company is scaling in the fast-growing market for musculoskeletal treatments and leverages a reach of over 25 million insured lives to expand into adjacent chronic indications. High gross margins and operational profitability are compelling, while demanding valuations and strong competitive pressure weigh on the outlook. » Mais em finanzen.net
Hinge Health raises revenue guidance after surprisingly strong Q2
Hinge Health significantly exceeded revenue expectations in the second quarter and reported strong operating metrics. The company raised its revenue forecast for the current fiscal year. Its strategic expansion into the gastrointestinal area underscores additional long-term scaling potential and triggered a sharp jump in the share price. » Mais em finanzen.net
Dados financeiros da empresa
| (EUR) | junho de 2026 | YoY |
|---|---|---|
| Receitas | 186,47 mi | 58,01% |
| Ganho bruto | 161,18 mi | 94,32% |
| Ganho líquido | 38,28 mi | 107,84% |
| EBITDA | 39,86 mi | 108,11% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 8,24 bi |
Número de ações | 80,69 mi |
Máximo/mínimo de 52 semanas | € 105,01 - € 26,87 |
| Dividendos | Não |
Beta | 1,36 |
PER (PE Ratio) | 84,90 |
PEG (PEG Ratio) | 1,12 |
P/VC (PB Ratio) | 26,16 |
P/V (PS Ratio) | 12,81 |
Perfil da empresa
| Nome | HINGE HEALTH INC. |
| CEO | Daniel A. Perez |
| Colaboradores | 1.437 |